Inclusion Criteria:  Patients aged between 18 and 75 years Confirmed diagnosis of CAD using ASA 100 mg once a day. The following will be considered for CAD diagnosis: previous history of type 1 AMI (at least one year ago), according to the fourth universal definition of myocardial infarction (Thygesen, Alpert et al. 2018) and/or coronary angioplasty and/or coronary artery bypass graft surgery myocardium and/or coronary angiography showing at least 50% obstruction in one of the main epicardial vessels. Agreement to sign the free and informed consent form.  Exclusion Criteria:  Clinically active bleeding or clinically significant bleeding in the last year. Peptic ulcer active in the last 60 days Previous history of high gastrointestinal bleeding Hemoglobin <10 g / dl at randomization; Platelets <100,000 or >500,000 µ/L Need for lumbar puncture Atrial fibrillation Metal valve prosthesis Percutaneous coronary intervention (PCI) in the last 3 months with conventional stent and in the last 6 months with drug-eluting stent. Surgical myocardial revascularization (CABG) in the last 90 days Percutaneous coronary intervention (PCI) or surgical myocardial revascularization (CABG) planned within the next 60 days; Previous hemorrhagic stroke; Moderate or severe liver failure associated with coagulation disorders (Child-Pugh B or C) Hypersensitivity to edoxaban or formula components; Pregnant women or women of childbearing potential; Chronic kidney disease: glomerular filtration rate estimated at <50 mL/min/1.73m², calculated using the Cockcroft-Gault equation; Current or last 30 days use of anticoagulant or antiplatelet therapy, except ASA; Weight <60 kg; HAS-BLED score ≥ 3 points; Concomitant use of P-glycoprotein inhibitors such as azithromycin, clarithromycin, erythromycin, itraconazole, ketoconazole, verapamil, quinidine, except amiodarone; Concomitant use of P-glycoprotein inducers, such as Rifampicin; Known abuse of alcohol, drugs, or medications in the 12 months prior to consent for this study; Cancer therapy 5 years prior to consent for this study; Medicines that will further increase the risk of bleeding (such as nonsteroidal anti-inflammatory drugs). Participation in another study within 30 days of signing the consent form.